Authors


Emanuele Zucca, MD

Latest:

The Management of Nongastric MALT Lymphomas

No definite guidelines exist for the management of nongastric MALT lymphoma. Retrospective series have included patients treated with different modalities, and excellent cause-specific and overall survival have been demonstrated, independent of the type of treatment adopted.


Emil Christensen

Latest:

Biomarkers Could Predict Bladder Cancer Progression

This video examines a study that used liquid biopsies to monitor disease progression in patients with bladder cancer.


Emili Montserrat, MD

Latest:

CLL Therapy: The Increasing Importance of Predictive Markers

It is easy to anticipate that as the complex biology of CLL continues to unfold, new prognostic and predictive biomarkers will be recognized. The discovery of genetic mutations that are key regulators of the development, growth, and proliferation of CLL leukemic cells augurs an alluring future.


Emiliano Calvo, MD, PhD

Latest:

Principles of Oncologic Pharmacotherapy

The effective use of cancer chemotherapy requires a thorough understanding of the principles of neoplastic cell growth kinetics, basic pharmacologic mechanisms of drug action, pharmacokinetic and pharmacodynamic variability, and mechanisms of drug resistance. Recent scientific advances in the field of molecular oncology have led to the identification of large numbers of potential targets for novel anticancer therapies. This has resulted in a tremendous expansion of the drug development pipeline, and in the present era, the diversity of clinically useful novel anticancer therapeutic agents is growing at an unprecedented rate. However, the great enthusiasm that surrounds these new agents must be tempered by the challenges they present in optimizing their clinical use and in rationally integrating them with existing anticancer therapies. This discussion focuses on the basic principles underlying the development of modern combination chemotherapy, and it is followed by a description of the major classes of chemotherapeutic drugs and their mechanisms of action.


Emilio Bombardieri, MD

Latest:

Nuclear Medicine Imaging in Breast Cancer: Current Strategies and Future Directions

The article “PET Scan in the Diagnosis and Management of Breast Cancer” by Jame Abraham and coworkers is a complete, updated review of the existing scientific literature about clinical indications for positron-emission tomography (PET) in this malignancy.


Emily Conant, MD

Latest:

Breast Imaging Pioneer Sheds Light on Screening Technology

Dr. Conant is a pioneer in the development of digital mammography, and a leader in research on the use and benefits of early mammography screening and on the role of MRI and PET scanning. She is also the recipient of grants from the National Institutes of Health to compare standard surgical biopsy with digital mammography and stereotactic core breast biopsy.


Emily H. Castellanos, MD

Latest:

Treatment of Early-Stage Pancreatic Cancer

Early trials of adjuvant therapy in pancreatic cancer had multiple limitations including small sample size, population heterogeneity, and inability to distinguish between components of combined modality treatment.


Emily Hayes

Latest:

Study may answer critics' fears about preop breast MRI

Greater utilization of dynamic contrast-enhanced MRI at the University of California, San Diego, over a 6-year period helped improve surgery planning for tough breast cancer cases without hiking mastectomy rates


Emily Keung, MD

Latest:

Neoadjuvant Therapy for Soft-Tissue Sarcomas

The aim of this review is to discuss current neoadjuvant treatment options for soft-tissue sarcomas.


Emily S. Tonorezos, MD, MPH

Latest:

Non–Small-Cell Lung Cancer After Mantle Radiation: A Case Report and Brief Review

In this case report, we present a non-Hodgkin lymphoma survivor who was incidentally found to have non–small-cell lung cancer 30 years after undergoing treatment that included mantle radiation. We discuss the treatment-related risk factors for lung cancer in this population and potential implications for long-term follow-up.


Emily Shacter, PhD

Latest:

Chronic Inflammation and Cancer: The Role of the Mitochondria

We review the evidence implicating a strong association between chronic inflammation and cancer, with an emphasis on colorectal and lung cancer.


Emma Rossi, MD

Latest:

COUNTERPOINT: Is Lymphadenectomy Required in Endometrial Cancer for Adequate Surgical Staging?

The question that should be posed to those who advocate for lymphadenectomy as a tool to guide the adjuvant therapy of endometrial cancer is: At what cost to the patient is lymphadenectomy performed?


Emmanuel F. Petricoin Iii, PhD

Latest:

Proteomics to Diagnose Human Tumors and Provide Prognostic Information

Proteomics is a rapidly emerging scientific discipline that holds greatpromise in identifying novel diagnostic and prognostic biomarkers forhuman cancer. Technologic improvements have made it possible to profileand compare the protein composition within defined populationsof cells. Laser capture microdissection is a tool for procuring pure populationsof cells from human tissue sections to be used for downstreamproteomic analysis. Two-dimensional polyacrylamide gel electrophoresis(2D-PAGE) has been used traditionally to separate complex mixturesof proteins. Improvements in this technology have greatly enhancedresolution and sensitivity providing a more reproducible and comprehensivesurvey. Image analysis software and robotic instrumentationhave been developed to facilitate comparisons of complex protein expressionpatterns and isolation of differentially expressed proteins spots.Differential in-gel electrophoresis (DIGE) facilitates protein expressionby labeling different populations of proteins with fluorescent dyes.Isotope-coded affinity tagging (ICAT) uses mass spectroscopy for proteinseparation and different isotope tags for distinguishing populationsof proteins. Although in the past proteomics has been primarilyused for discovery, significant efforts are being made to developproteomic technologies into clinical tools. Reverse-phase protein arraysoffer a robust new method of quantitatively assessing expressionlevels and the activation status of a panel of proteins. Surface-enhancedlaser-desorption/ionization time-of-flight (SELDI-TOF) mass spectroscopyrapidly assesses complex protein mixtures in tissue or serum. Combinedwith artificial intelligence–based pattern recognition algorithms,this emerging technology can generate highly accurate diagnostic information.It is likely that mass spectroscopy–based serum proteomicswill evolve into useful clinical tools for the detection and treatment ofhuman cancers.


Emmanuel S. Antonarakis, MD

Latest:

Marker Predicts Outcomes in mCRPC Treated With AR-Targeted Therapy

This video examines the results of a study that looked at the prognostic value of androgen receptor full-length detection using a CTC-based mRNA assay in metastatic castration-resistant prostate cancer patients starting treatment with AR-targeted agents.


Emmy Ludwig, MD

Latest:

Screening and Prevention of Hepatitis B Virus Reactivation During Chemotherapy

The incidence of both hepatitis B virus infection and cancer is common. The use of immunosuppressive therapy in patients with hepatitis B virus can result in reactivation of hepatitis B virus, which can, in turn, lead to significant morbidity and mortality.


Encarna González, MD

Latest:

Biweekly Gemcitabine, Doxorubicin, and Paclitaxel as First-Line Treatment in Metastatic Breast Cancer

In a single-center, open, phase II trial, we assessed the toxicity and activity of a triple combination therapy-doxorubicin at 30 mg/m2 (day 1), paclitaxel (Taxol) at 135 mg/m2 (day 2), and gemcitabine (Gemzar) at 2,500 mg/m2


Enrique A. Diaz-canton, MD

Latest:

Colorectal Cancer: Diagnosis and Management

In the United States, cancer of the large bowel is the second most common cause of cancer deaths after cancer of the lung [1]. 1995 estimates place large bowel cancer as the third most common malignancy, behind lung and prostate carcinomas in men and behind lung and breast cancers in women.


Enrique Aranda, MD, PhD

Latest:

UFT Plus or Minus Calcium Folinate for Metastatic Colorectal Cancer in Older Patients

Two studies were carried out to determine the activity and evaluate the toxicity of oral chemotherapy with uracil and tegafur in a 4:1 molar ratio (UFT) plus or minus calcium folinate in elderly patients with advanced colorectal


Enrique Espinosa, MD

Latest:

The UFT/Leucovorin/Etoposide Regimen for the Treatment of Advanced Gastric Cancer

Gastric cancer is the most chemosensitive adenocarcinoma among digestive neoplasms. A few years ago, we performed a phase II trial with the FLEP regimen, in which fluorouracil (5-FU) and leucovorin are combined


Enrique Hernandez, MD, FACOG, FACS

Latest:

Commentary (Hernandez): Surgical Staging in Endometrial Cancer

Kirby et al are correct in theirstatement that continued controversysurrounds the comprehensivesurgical staging of all patientswith clinical stage I endometrialadenocarcinoma. Such is the case becauselymph node metastasis is foundin only 10% of these patients. Theproportion of patients found to havelymph node metastasis is even loweramong those with grade 1 and 2 tumorswith minimal or no invasion. Ahigh proportion of patients with endometrialadenocarcinoma fall intothis group.


Enrique Murillo, MD

Latest:

UFT in Combination as Adjuvant Therapy for Breast Cancer

Between 1989 and 1993, 409 evaluable patients with breast cancer have been treated with tegafur and uracil (UFT) in an adjuvant setting in two different trials. Data from both trials were reviewed in December 1995 after a


Enrique Torrija, MD

Latest:

UFT in Combination as Adjuvant Therapy for Breast Cancer

Between 1989 and 1993, 409 evaluable patients with breast cancer have been treated with tegafur and uracil (UFT) in an adjuvant setting in two different trials. Data from both trials were reviewed in December 1995 after a


Enzo Galligioni, MD

Latest:

Gemcitabine/Epirubicin/Paclitaxel Trials in Advanced Breast Cancer

Numerous trials have shown that the pharmacokinetic interferences of epirubicin (Ellence)/paclitaxel (Taxol) combinations produce less pharmacodynamic effect than doxorubicin/paclitaxel regimens. Paclitaxel is more easily


Eric A. Klein, MD

Latest:

A Rational Approach to Managing Prostate Cancer in an Irrational Time

The chairman of the Glickman Urological & Kidney Institute at the Cleveland Clinic provides commentary and an adjacent perspective to the Duke Cancer Institute report.


Eric Bleickardt, MD

Latest:

Camptothecin and Taxane Regimens for Small-Cell Lung Cancer

For more than 2 decades, combination chemotherapy has been the standard treatment for patients with small-cell lung cancer. Despite high initial response rates in both extensive- and limited-stage disease, long-term survival


Eric Chow, MD, MPH

Latest:

Childhood Cancer Survivors: Cured but With Long-Term Health Risks

This evolving issue is increasingly concerning, as studies regarding the causes of non-relapse late mortality in childhood cancer survivors consistently include cardiovascular disease as one of the major contributors to this mortality risk.


Eric D. Blom, PhD

Latest:

Current Status of Voice Restoration Following Total Laryngectomy

Total laryngectomy is the surgical procedure traditionally used to treat patients with advanced-stage cancer of the larynx. The impairments resulting from removal of such a small organ are, indeed, profound. They include


Eric G. Davis, MD

Latest:

An Argument for Aggressive Resection in Melanoma

Any minimization of therapy in the name of reducing morbidity requires careful consideration. Reducing morbidity in melanoma is certainly a laudable goal, but locoregional disease control and cure must remain our primary objectives.



Eric J. Bow, MD, MSc, DBacteriol, FRCP

Latest:

Commentary (Harding/Bow): Infectious Complications of Lung Cancer

Lung cancer is the most commoncause of cancer-relatedmortality in the United Statesand worldwide.[1] In the UnitedStates, lung cancer was responsiblefor an estimated 160,440 deaths in2004. This surpassed the combinedmortality resulting from colorectal,breast, and prostate cancer.